©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessParathyroid cancer, differential diagnosis

Summary

Short information

Comprehensive differential diagnostic panel for Parathyroid cancer comprising 7 guideline-curated genes and altogether 12 curated genes according to the clinical signs

ID
NP8855
Number of genes
11 Accredited laboratory test
Examined sequence length
10,2 kb (Core-/Core-canditate-Genes)
18,8 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
Material
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications

NGS +

{Sanger]

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity
CDC731596NM_024529.5AD
CDKN1B597NM_004064.5AD
MEN11833NM_130799.2AD
RB12787NM_000321.3Sus
RET3345NM_020975.6n.k.
AP2S1429NM_004069.6AD
CASR3237NM_000388.4AD, AR
GCM21521NM_004752.4AD, AR
GNA111080NM_002067.5AD
PRKAR1A1146NM_002734.5n.k.
TP531182NM_000546.6AD

Informations about the disease

Clinical Comment

n about 90% of cases, an early sign of parathyroid cancer is hyperparathyroidism with hypercalcemic crisis. Neurologic and psychiatric problems may develop, as well as renal and bone complications. Mutations in the CDC73 gene are found in up to 70% of parathyroid cancer cases. In about one-third of affected individuals with changes in this gene, the mutation is inherited. Parathyroid cancer occurs in 15% of individuals with hyperparathyroidism-pineal tumor syndrome and in 1% of patients with familial isolated hyperparathyroidism. Both conditions are also caused by mutations in the CDC73 gene. In rare cases, parathyroid cancer has also been found in patients with multiple endocrine neoplasia (MEN1). Mutations in other genes may also contribute to the development of parathyroid cancer. A negative DNA result does not exclude the clinical diagnosis.

Reference: https://www.ncbi.nlm.nih.gov/books/NBK3789/

 

Synonyms
  • Allelic: Acrodysostosis 1, with/-out hormone resistance (PRKAR1A)
  • Allelic: Adrenocortical carcinoma, pediatric (TP53)
  • Allelic: Adrenocortical tumor, somatic (PRKAR1A)
  • Allelic: Basal cell carcinoma 7 (TP53)
  • Allelic: Bone marrow failure syndrome 5 (TP53)
  • Allelic: Central hypoventilation syndrome, congenital (RET)
  • Allelic: Choroid plexus papilloma (TP53)
  • Allelic: Colorectal cancer (TP53)
  • Allelic: Epilepsy idiopathic generalized, susceptibility to, 8 (CASR)
  • Allelic: Glioma susceptibility 1 (TP53)
  • Allelic: Hirschsprung disease, protection against (RET)
  • Allelic: Hirschsprung disease, susceptibility to, 1 (RET)
  • Allelic: Hypocalcemia, AD (CASR)
  • Allelic: Hypocalcemia, AD 2 (GNA11)
  • Allelic: Hypocalcemia, AD, with Bartter syndrome (CASR)
  • Allelic: Hypoparathyroidism, familial isolated 2 (GCM2)
  • Allelic: Li-Fraumeni syndrome (TP53)
  • Allelic: Medullary thyroid carcinoma (RET)
  • Allelic: Myxoma, intracardiac (PRKAR1A)
  • Allelic: Osteosarcoma (TP53)
  • Allelic: Pheochromocytoma (RET)
  • Allelic: Pigmented nodular adrenocortical disease, primary, 1 (PRKAR1A)
  • Allelic: Pituitary adenoma 1, multiple types (AIP)
  • Allelic: Pituitary adenoma predisposition (AIP)
  • Carney complex, type 1 (PRKAR1A)
  • Endocrine cancer [panelapp] (TP53)
  • Hyperparathyroidism 4 (GCM2)
  • Hyperparathyroidism, neonatal (CASR)
  • Hyperparathyroidism-jaw tumor syndrome (CDC73)
  • Hypocalciuric hypercalcemia, type I (CASR)
  • Hypocalciuric hypercalcemia, type II (GNA11)
  • Hypocalciuric hypercalcemia, type III (AP2S1)
  • Multiple endocrine neoplasia I (MEN1)
  • Multiple endocrine neoplasia IIA + IIB (RET)
  • Multiple endocrine neoplasia IV (CDKN1B)
  • Parathyroid adenoma with cystic changes (CDC73)
  • Parathyroid carcinoma (CDC73)
  • Retinoblastoma (RB1)
  • Retinoblastoma, trilateral (RB1)
Heredity, heredity patterns etc.
  • AD
  • AR
  • Sus
  • n.k.
OMIM-Ps
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

No text defined